Navigation Links
The CementBloc and Novartis Vaccines to Jointly Present Top Considerations in Interactive Selling at the 11th Annual iPharmaConnect
Date:3/21/2012

NEW YORK, March 21, 2012 /PRNewswire/ -- Meghan Lopresto, VP, Sales Force Automation Analytics at The CementBloc, and Emad Abdelnaby, Director of Marketing at Novartis Vaccines, will be co-presenting their expertise in interactive selling at CBI's iPharmaConnect plenary session on March 27, 2012, in Philadelphia.

The conference is a 3-day symposium that will unite senior-level marketing, digital, brand, and medical affairs professionals to discuss novel approaches to thriving multichannel digital campaigns. From the client and agency perspectives, Ms. Lopresto and Mr. Abdelnaby will be presenting the success story behind the recently rolled-out program at Novartis Vaccines. Their talk, entitled, "Develop a Road Map for Transforming Your Organization Through Interactive Selling" will serve as an essential blueprint for optimizing iPad selling across an organization. 

"Transitioning your field sales team over to an iPad platform is more than just an upgrade of their technology," says Ms. Lopresto. "It represents a key shift in the engagement between sales representatives and their customers. A successful rollout of these new tools requires a defined road map of the process, including agreed-upon core principles and buy-in from multiple stakeholders. If this is achieved, an organization can be transformed, for the better, through interactive selling."

At The CementBloc, Ms. Lopresto plays a key role in interactive selling tool development and measurement, multichannel marketing planning and analytics, promotional spend optimization, CRM/PRM, and closed-loop marketing initiatives. For more than 10 years, Meghan has been in the pharmaceutical industry in leadership roles, providing clients with innovative solutions for multichannel and professional advertising campaigns. 

As Director of Marketing for the US Meningococcal Franchise at Novartis Vaccines and Diagnostics (NVD), Mr. Abdelnaby has responsibility for the development of professionally directed strategies and resources. Through his work at Novartis, Mr. Abdelnaby has helped to continue NVD's commitment to innovation in this space, including adoption of a broad-scale iPad platform for physician detailing, CRM, and sales training. 

For more information or to register for iPharmaConnect, please contact CBI at 1-800-817-8601.

About The CementBloc: The CementBloc is a leading multichannel health and wellness creative agency based in New York. Founded in 2000 by Susan Miller and Rico Viray, The CementBloc is also a founding member of Indigenus, an independent global network of entrepreneurial healthcare creative agencies.

vwww.thecementbloc.com


'/>"/>
SOURCE The CementBloc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ira Haimowitz, PhD, EVP, Group Director, Intelligence and Analytics at The CementBloc, to Present at Aberdeen Group Inaugural Business Analytics Summit
2. Ira Haimowitz, PhD, EVP, at The CementBloc, to Present on Best Practices in iPad Interactive Selling at 11th Annual ePharma Summit™
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
8. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
9. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
10. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
11. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):